» Articles » PMID: 36139025

Oroxylin A: A Promising Flavonoid for Prevention and Treatment of Chronic Diseases

Abstract

There have been magnificent advancements in the understanding of molecular mechanisms of chronic diseases over the past several years, but these diseases continue to be a considerable cause of death worldwide. Most of the approved medications available for the prevention and treatment of these diseases target only a single gene/protein/pathway and are known to cause severe side effects and are less effective than they are anticipated. Consequently, the development of finer therapeutics that outshine the existing ones is far-reaching. Natural compounds have enormous applications in curbing several disastrous and fatal diseases. Oroxylin A (OA) is a flavonoid obtained from the plants , , and , which have distinctive pharmacological properties. OA modulates the important signaling pathways, including NF-κB, MAPK, ERK1/2, Wnt/β-catenin, PTEN/PI3K/Akt, and signaling molecules, such as TNF-α, TGF-β, MMPs, VEGF, interleukins, Bcl-2, caspases, HIF-1α, EMT proteins, Nrf-2, etc., which play a pivotal role in the molecular mechanism of chronic diseases. Overwhelming pieces of evidence expound on the anti-inflammatory, anti-bacterial, anti-viral, and anti-cancer potentials of this flavonoid, which makes it an engrossing compound for research. Numerous preclinical and clinical studies also displayed the promising potential of OA against cancer, cardiovascular diseases, inflammation, neurological disorders, rheumatoid arthritis, osteoarthritis, etc. Therefore, the current review focuses on delineating the role of OA in combating different chronic diseases and highlighting the intrinsic molecular mechanisms of its action.

Citing Articles

Inhibition of TFAM-Mediated Mitophagy by Oroxylin A Restored Sorafenib Sensitivity Under Hypoxia Conditions in HepG2 Cells.

Ji S, Xu X, Li Y, Sun S, Fu Q, Qiu Y Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770569 PMC: 11676196. DOI: 10.3390/ph17121727.


Research Progress of in the Treatment of Gastrointestinal Cancer.

Wang L, Ni B, Wang J, Zhou J, Wang J, Jiang J Integr Cancer Ther. 2024; 23:15347354241302049.

PMID: 39610320 PMC: 11605761. DOI: 10.1177/15347354241302049.


Combination effect of flavonoids attenuates lung cancer cell proliferation by inhibiting the STAT3 and FAK signaling pathway.

Wan P, Li X, Guo S, Zhao X Open Life Sci. 2024; 19(1):20220977.

PMID: 39588118 PMC: 11588013. DOI: 10.1515/biol-2022-0977.


Aging, ROS, and cellular senescence: a trilogy in the progression of liver fibrosis.

Almalki W, Salman Almujri S Biogerontology. 2024; 26(1):10.

PMID: 39546058 DOI: 10.1007/s10522-024-10153-3.


Suppression of neuronal CDK9/p53/VDAC signaling provides bioenergetic support and improves post-stroke neuropsychiatric outcomes.

Xia J, Zhang T, Sun Y, Huang Z, Shi D, Qin D Cell Mol Life Sci. 2024; 81(1):384.

PMID: 39235466 PMC: 11377386. DOI: 10.1007/s00018-024-05428-4.


References
1.
Ong P, Wang L, Dai X, Tseng S, Loo S, Sethi G . Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Front Pharmacol. 2016; 7:395. PMC: 5079084. DOI: 10.3389/fphar.2016.00395. View

2.
Liu C, Chen M, Tseng T, Chen L, Kuo J, Lee T . Oroxylin a, but not vasopressin, ameliorates cardiac dysfunction of endotoxemic rats. Evid Based Complement Alternat Med. 2012; 2012:408187. PMC: 3489109. DOI: 10.1155/2012/408187. View

3.
Mangal P, Khare P, Jagtap S, Bishnoi M, Kondepudi K, Bhutani K . Screening of six Ayurvedic medicinal plants for anti-obesity potential: An investigation on bioactive constituents from Oroxylum indicum (L.) Kurz bark. J Ethnopharmacol. 2016; 197:138-146. DOI: 10.1016/j.jep.2016.07.070. View

4.
Zhang Z, Lian X, Li S, Stringer J . Characterization of chemical ingredients and anticonvulsant activity of American skullcap (Scutellaria lateriflora). Phytomedicine. 2008; 16(5):485-93. DOI: 10.1016/j.phymed.2008.07.011. View

5.
Muralimanoharan S, Kunnumakkara A, Shylesh B, Kulkarni K, Haiyan X, Ming H . Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells. Prostate. 2008; 69(5):494-504. PMC: 2674392. DOI: 10.1002/pros.20899. View